New Treatment Options in Adenoid Cystic Carcinoma (ACC), Updates from ASCO 2026

Prof Kevin Harrington presents an update on new treatment options for Adenoid Cystic Carcinoma (ACC), shared as part of the ASCO 2026 meeting.

Exciting new clinical trial developments for ACC patients were highlighted at that meeting and there is news of one trial to open in the UK.

References below:

REM-422 (Remix Therapeutics)
Ferrarotto R, Swiecicki P, Ho AL, Algazi AP, McKean M, Webster J, Koneru M, Kung C, Hanna GJ. Clinical activity of REM-422, a MYB mRNA degrader, in recurrent/metastatic adenoid cystic carcinoma: Final results from the phase 1/2 dose-escalation cohort. Journal of Clinical Oncology. 2026;44(16_suppl):6009. doi:10.1200/JCO.2026.44.16_suppl.6009. [ascopubs.org]

RGT-61159 (Rgenta Therapeutics)
Ho AL, Sanz Garcia E, Ferrarotto R, Swiecicki P, Spira A, Hilton JF, Li Z, Rodriguez CP, Adkins D, Xi HS, Soulard P, Wager T, Memari S, Vali S, Jameson KL, Barrera I, Walling JM, Hanna GJ. A phase 1a/b study of RGT-61159, an oral MYB splicing modulator, in patients with advanced adenoid cystic carcinoma and colorectal cancer. Journal of Clinical Oncology. 2026;44(16_suppl):3089. doi:10.1200/JCO.2026.44.16_suppl.3089. [ascopubs.org]

Emiltatug ledadotin (XMT-1660; Emi-Le)
Hanna GJ, Rabinowits G, Attarian S, Solomon BM, McAndrew NP, Naqash AR, Ho AL, Abushahin LI, Bradshaw C, Zizlsperger N, Burger RA, Barry E, Ferrarotto R. Emiltatug ledadotin (Emi-Le), a B7-H4–directed antibody-drug conjugate (ADC), in patients with aggressive adenoid cystic carcinoma (ACC): Phase 1 interim analysis. Journal of Clinical Oncology. 2026;44(16_suppl):6010. doi:10.1200/JCO.2026.44.16_suppl.6010. [ascopubs.org]